RET and neoplasm: BOS172738 demonstrated broad anti-tumor activity with an ORR of 33% (n = 18/54), an NSCLC ORR of 33% (n = 10/30), and MTC ORR of 44% (n = 7/16, including one complete response), and one patient with RET fusion–positive pancreatic cancer reported a partial response.